351 related articles for article (PubMed ID: 3099236)
1. Prolactin secretion after surgery or bromocriptine treatment of prolactinoma.
De Leo V; Petraglia F; Sardelli S; Danero S; Genazzani AR; D'Antona N
Obstet Gynecol; 1987 Jan; 69(1):99-103. PubMed ID: 3099236
[TBL] [Abstract][Full Text] [Related]
2. Defective regulation of prolactin secretion after successful removal of prolactinomas.
Camanni F; Ghigo E; Ciccarelli E; Massara F; Campagnoli C; Molinatti G; Müller EE
J Clin Endocrinol Metab; 1983 Dec; 57(6):1270-6. PubMed ID: 6415087
[TBL] [Abstract][Full Text] [Related]
3. Direct effects of catecholamines, thyrotropin-releasing hormone, and somatostatin on growth hormone and prolactin secretion from adenomatous and nonadenomatous human pituitary cells in culture.
Ishibashi M; Yamaji T
J Clin Invest; 1984 Jan; 73(1):66-78. PubMed ID: 6140273
[TBL] [Abstract][Full Text] [Related]
4. Bromocriptine treatment of microprolactinomas: evidence of stable prolactin decrease after drug withdrawal.
Moriondo P; Travaglini P; Nissim M; Conti A; Faglia G
J Clin Endocrinol Metab; 1985 Apr; 60(4):764-72. PubMed ID: 3919052
[TBL] [Abstract][Full Text] [Related]
5. Hypothalamic-pituitary function following bromocriptine therapy in patients with prolactinomas.
Badawy SZ; Notman DD; Sunderlin FS; Springer JM; Streeten DH; Omar MM; Marshall LD
J Reprod Med; 1982 Mar; 27(3):139-45. PubMed ID: 6806469
[TBL] [Abstract][Full Text] [Related]
6. Macroprolactinomas and functionless pituitary tumours. Immunostaining and effect of dopamine agonist therapy.
Gasser RW; Mueller-Holzner E; Skrabal F; Finkenstedt G; Mayr U; Tabarelli M; Spoendlin H; Grunert V; Twerdy K
Acta Endocrinol (Copenh); 1987 Oct; 116(2):253-9. PubMed ID: 3116800
[TBL] [Abstract][Full Text] [Related]
7. Prolactin and thyrotropin responses to thyrotropin-releasing hormone in patients with secondary amenorrhea: the effect of bromocriptine.
Hirvonen E; Ranta T; Seppäla M
J Clin Endocrinol Metab; 1976 Jun; 42(6):1024-30. PubMed ID: 819453
[TBL] [Abstract][Full Text] [Related]
8. Tissue kallikrein and the effect of bromocriptine in human prolactin and growth hormone-secreting pituitary adenomas.
Jones TH; Figueroa CD; Smith CM; Bhoola KD
Agents Actions Suppl; 1992; 38 ( Pt 2)():175-82. PubMed ID: 1462825
[TBL] [Abstract][Full Text] [Related]
9. Hormonal regulation of prolactin release by human prolactinoma cells cultured in serum-free conditions.
Jaquet P; Gunz G; Grisoli F
Horm Res; 1985; 22(3):153-63. PubMed ID: 3932176
[TBL] [Abstract][Full Text] [Related]
10. [Primary hyperprolactinemic amenorrhea. Report of 4 patients].
Rudolf K; Smid I; Kunkel S; Bazsa-Kassai Z
Zentralbl Gynakol; 1985; 107(14):894-8. PubMed ID: 3929499
[TBL] [Abstract][Full Text] [Related]
11. Is idiopathic hyperprolactinemia a transitional stage toward prolactinoma?
Pereira MC; Sobrinho LG; Afonso AM; Ferreira JM; Santos MA; Sousa MF
Obstet Gynecol; 1987 Sep; 70(3 Pt 1):305-8. PubMed ID: 3114691
[TBL] [Abstract][Full Text] [Related]
12. Low recurrence rate after partial hypophysectomy for prolactinoma: the predictive value of dynamic prolactin function tests.
Webster J; Page MD; Bevan JS; Richards SH; Douglas-Jones AG; Scanlon MF
Clin Endocrinol (Oxf); 1992 Jan; 36(1):35-44. PubMed ID: 1559298
[TBL] [Abstract][Full Text] [Related]
13. Pathological study of thyrotropin-secreting pituitary adenoma: plurihormonality and medical treatment.
Teramoto A; Sanno N; Tahara S; Osamura YR
Acta Neuropathol; 2004 Aug; 108(2):147-53. PubMed ID: 15185102
[TBL] [Abstract][Full Text] [Related]
14. Effect of thyrotropin-releasing hormone and bromoergocriptine on growth hormone and prolactin secretion in perfused pituitary adenoma tissues of acromegaly.
Ishibashi M; Yamaji T
J Clin Endocrinol Metab; 1978 Dec; 47(6):1251-6. PubMed ID: 122426
[TBL] [Abstract][Full Text] [Related]
15. Evidence of abnormal dopaminergic control of prolactin in patients with hypothalamic and pituitary tumors.
Cabranes JA; Almoguera I; del Olmo J; Prensa A; Pablos I; Charro AL
J Med; 1986; 17(1):25-39. PubMed ID: 3035040
[TBL] [Abstract][Full Text] [Related]
16. A human pituitary adenoma secreting thyrotropin and prolactin: immunohistochemical, biochemical, and cell culture studies.
Jaquet P; Hassoun J; Delori P; Gunz G; Grisoli F; Weintraub BD
J Clin Endocrinol Metab; 1984 Nov; 59(5):817-24. PubMed ID: 6480809
[TBL] [Abstract][Full Text] [Related]
17. Perifusion studies of bromocriptine-treated and untreated macroprolactinomas: effects of dopamine, bromocriptine and TRH.
Bevan JS; Burke CW
Clin Endocrinol (Oxf); 1989 Jun; 30(6):667-80. PubMed ID: 2512041
[TBL] [Abstract][Full Text] [Related]
18. Rapid regression of pituitary prolactinomas during bromocriptine treatment.
Thorner MO; Martin WH; Rogol AD; Morris JL; Perryman RL; Conway BP; Howards SS; Wolfman MG; MacLeod RM
J Clin Endocrinol Metab; 1980 Sep; 51(3):438-45. PubMed ID: 6773972
[TBL] [Abstract][Full Text] [Related]
19. [Alteration of prolactin secretion after transsphenoidal adenomectomy for prolactinomas].
Yokoyama M
No To Shinkei; 1990 Aug; 42(8):773-9. PubMed ID: 2223270
[TBL] [Abstract][Full Text] [Related]
20. Does bromocriptine block thyrotropin-releasing hormone-induced prolactin release during pregnancy?
Ylikorkala O; Kivinen S; Rönnberg L; Viinikka L
J Clin Endocrinol Metab; 1980 Mar; 50(3):600-2. PubMed ID: 6766949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
